Non-Destructive Hardness Testing

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

whitePaper | December 28, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical.

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.